Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors

Journal of Medicinal Chemistry

Volumn 48, Issue 15, 2005, Pages 4834-4841

  Cecchi, Alessandro ^a   Hulikova, Alzbeta ^b   Pastorek, Jaromír ^b   Pastoreková, Silvia ^b   Scozzafava, Andrea ^a   Winum, Jean Yves ^c   Montero, Jean Louis ^c   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b INSTITUTE OF VIROLOGY   (Slovakia)

^c INSTITUT CHARLES GERHARDT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(4 SULFAMOYLPHENYL)THIOUREIDOFLUORESCEIN; 4 AMINOETHYLBENZENESULFONAMIDE; ACETAZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CARBONIC ANHYDRASE IX INHIBITOR; DICLOFENAMIDE; ETHOXZOLAMIDE; INDISULAM; ISOENZYME; METHAZOLAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

ACID BASE BALANCE; ACIDIFICATION; ACIDOSIS; ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DESIGN; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME MECHANISM; FLUORESCENCE; HUMAN; HUMAN CELL; HYPOXIA; ION TRANSPORT; MICROENVIRONMENT; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CATALYTIC DOMAIN; CELL HYPOXIA; CELL LINE; CELL MEMBRANE PERMEABILITY; DOGS; ERYTHROCYTE MEMBRANE; EXTRACELLULAR FLUID; FLUORESCENT DYES; HUMANS; HYDROGEN-ION CONCENTRATION; ISOENZYMES; MUTATION; SEQUENCE DELETION; SULFONAMIDES;

EID: 22744446294     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0501073     Document Type: Article

References (42)

1. (a) Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inibitors. Med. Res. Rev. 2003, 23, 146-189.
2. (b) Supuran, C. T., Scozzafava, A., Conway, J., Eds. Carbonic Anhydrase - Its Inhibitors and Activators; CRC Press (Taylor and Francis Group): Boca Raton, FL, 2004; pp 1-363 and references therein.
3. (c) Casini, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets 2002, 2, 55-75.
4. (a) Pastorekova, S.; Pastorek, J. Cancer-related carbonic anhydrase isozymes. In Carbonic Anhydrase - Its Inhibitors and Activators; Supuran, C. T., Scozzafava, A., Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 253-280.
5. (b) Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229.
6. (c) Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C. T. Anticancer and antiviral sulfonamides. Curr. Med. Chem. 2003, 10, 925-953.
7. (a) Parkkila, S.; Rajaniemi, H.; Parkkila, A. K.; Kivela, J.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W. S. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2220-2224.
8. (b) Teicher, B. A.; Liu, S. D.; Liu, J. T.; Holden, S. A.; Herman, T. S. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 1993, 13, 1549-1556.
9. (a) Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents? Eur. J. Med. Chem. 2000, 35, 867-874.
10. (b) Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors: Aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. J. Enzyme Inhib. 2000, 15, 597-610.
11. (a) Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis of N-morpholyl-thiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV. Bioorg. Med. Chem. Lett. 2000, 10, 1117-1120.
12. (b) Supuran, C. T.; Briganti, F.; Tilli, S.; Chegwidden, W. R.; Scozzafava, A. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? Bioorg. Med. Chem. 2001, 9, 703-714.
13. (a) Pastorek, J.; Pastorekova, S.; Callebaut, I.; Mornon, J. P.; Zelnik, V.; Opavsky, R.; Zatovicova, M.; Liao, S.; Portetelle, D.; Stanbridge, E. J.; Zavada, J.; Burny, A.; Kettmann, R. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994, 9, 2788-2888.
14. (b) Opavsky, R.; Pastorekova, S.; Zelnik, V.; Gibadulinova, A.; Stanbridge, E. J.; Zavada, J.; Kettmann, R.; Pastorek, J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationship. Genomics 1996, 33, 480-487.
15. Tureci, O.; Sahin, U.; Vollmar, E.; Siemer, S.; Gottert, E.; Seitz, G.; Parkkila, A. K.; Shah, G. N.; Grubb, J. H.; Pfreundschuh, M.; Sly, W. S. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 7608-7613.
16. Wykoff, C. C.; Beasley, N. J.; Watson, P. H.; Turner, K. J.; Pastorek, J.; Sibtain, A.; Wilson, G. D.; Turley, H.; Talks, K. L.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. Hypoxia-inducible regulation of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075-7083.
17. Potter, C. P. S.; Harris, A. L. Diagnostics, prognostics and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer 2003, 89, 2-7.
18. Svastova, E.; Zilka, N.; Zatovicova, M.; Gibadulinova, A.; Ciampor, F.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. Exp. Cell Res. 2003, 290, 332-345.
19. Svastova, E.; Hulikova, A.; Rafajova, M.; Zatovicova, M.; Gibadulinova, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439-445.
20. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
21. (a) Stubbs, M.; McSheehy, P. M. J.; Griffiths, J. R.; Bashford, C. L. Causes and consequences of tumor acidity and implications for treatment. Mol. Med. Today 2000, 6, 15-19.
22. (b) Helmlinger, G.; Sckell, A.; Dellian, M.; Forbes, N. S.; Jain, R. K. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 2002, 8, 1284-1291.
23. (a) Fukumura, D.; Xu, L.; Chen, Y.; Gohongi, T.; Seed, B.; Jain, R. K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 2001, 61, 6020-6024.
24. (b) Kato, Y.; Nakayama, Y.; Umeda, M.; Miyazaki, K. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J. Biol. Chem. 1992, 267, 11424-11430.
25. Martinez-Zaguilan, R.; Lynch, R. M.; Martinez, G. M.; Gillies, R. J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis 1992, 14, 176-186.
26. Fischer, B.; Müller, B.; Fischer, K. G.; Baur, N.; Kreutz, W. Acidic pH inhibits non-MHC-restricted killer cell functions. Clin. Immunol. 2000, 96, 252-263.
27. (a) Casini, A.; Scozzafava, A.; Mincione, F.; Menabuoni, L.; Hies, M. A.; Supuran, C. T. Carbonic anhydrase inhibitors. Water soluble 4-sulfamoylphenyl-thioureas as topical intraocular pressure lowering agents with long lasting effects. J. Med. Chem. 2000, 43, 4884-4892.
28. (b) Innocenti, A.; Casini, A.; Alcaro, A. C.; Papini, A. M.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: The first on-resin screening of a 4-sulfamoylphenylthiourea library. J. Med. Chem. 2004, 47, 5224-5229.
29. Supuran, C. T.; Scozzafava, A.; Jurca, B. C.; Hies, M. A. Carbonic anhydrase inhibitors. Part 49. Synthesis of substituted ureido-and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I. Eur. J. Med. Chem. 1998, 33, 83-93.
30. Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. J. Biol. Chem. 1971, 246, 2561-2573.
31. Gomaa, Z. S. Determination of acetazolamide in dosage forms by high performance liquid chromatography. Biomed. Chromatogr. 1993, 7, 134-135.
32. Abdine, H.; Elsayed, M. A.; Elsayed, Y. M. pH-induced difference spectrophotometric assay of acetazolamide, hydrochlorothiazide and furosemide. J. Assoc. Off. Anal. Chem. 1978, 61, 695-701.
33. Wistrand, P. J.; Lindqvist, A. Design of carbonic anhydrase inhibitors and the relationship between the pharmacodymanics and pharmacokinetics of acetazolamide. In Carbonic Anhydrase - From Biochemistry and Genetics to Physiology and Clinical Medicine; Botrè, F., Gros, G., Storey, B. T., Eds.; VCH: Weinheim, Germany, 1991; pp 352-378.
34. Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-1009.
35. Scozzafava, A.; Briganti, F.; Hies, M.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfinamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J. Med. Chem. 2000, 43, 292-300.
36. Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-873.
37. (a) Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anti-cancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 217-223.
38. (b) Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550-557.
39. (a) Abbate, F.; Casini, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. J. Enzyme Inhib. Med. Chem. 2003, 18, 303-308.
40. (b) Casini, A.; Abbate, F.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X ray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamide-two heads are better than one? Bioorg. Med. Chem. Lett. 2003, 13, 2759-2763.
41. (c) Abbate, F.; Casini, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide. Bioorg. Med. Chem. Lett. 2004, 14, 2357-2361.
42. Supuran, C. T.; Scozzafava, A. Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor. J. Enzyme Inhib. Med. Chem. 2004, 19, 269-273.